Peptide Encyclopedia / Follistatin
EncyclopediaFollistatin is a protein that binds and inhibits myostatin and related TGF-beta signals, easing the brake on muscle growth. Gene-therapy versions sit in early human trials, injectable consumer products stay gray-market and unverified, and none carry FDA approval. Educational only, not medical advice.
| Category | Growth Hormone |
| Regulatory status | Not FDA-approved. |
A protein that binds and inhibits myostatin and related TGF-beta family members, reducing inhibition of muscle growth (myostatin antagonism promotes muscle mass).
Uncertain/variable; native follistatin protein has a very short circulating half-life (minutes), and delivery approaches differ greatly.
Not FDA-approved. Follistatin gene therapy has been studied in early-phase human trials (e.g., Becker and Duchenne muscular dystrophy) but is investigational. Injectable 'follistatin' sold to consumers is a gray-market product of uncertain identity. Myostatin inhibitors are prohibited by WADA.
Limited human safety data outside small gene-therapy trials. Theoretical concerns with strong myostatin inhibition (e.g., tendon/heart effects). Quality/content of consumer products is unverified.
Early human trials for the gene-therapy approach; consumer peptide use is anecdotal with minimal human data.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Follistatin may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
